Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.49 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.49 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.46 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.46 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.46 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30891041 | 1.00 | ALDH1A1 (0.49) | ALDH1A1TXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL620331 | 0.93 | ALDH1A1 (0.49) | ALDH1A1TXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL3720824 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL7307217 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL28008455 | 0.80 | ALDH1A1 (0.54) | ALDH1A1TXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL31439301 | 0.80 | ALDH1A1 (0.54) | ALDH1A1TXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL1551650 | 0.80 | SMN1; SMN2 (0.50) | ALDH1A1TXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL1259501 | 0.79 | CYP1A2 (0.55) | ALDH1A1TXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL31399941 | 0.79 | CYP1A2 (0.55) | ALDH1A1TXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL1207982 | 0.78 | ALDH1A1 (0.57) | ALDH1A1TXNRD1TXNRD3TXNRD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286429-B2 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-29 | — | — | US | disclosed |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| EP-4384493-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076581-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-113896744-B | Selective EGFR inhibitor | 成都先导药物开发股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230064443-A1 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-02 | — | — | US | disclosed |
| WO-2023016447-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| CN-113896744-A | Selective EGFR inhibitor | 成都先导药物开发股份有限公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-101921238-B | Preparation of substituted benzo-nitrogen heterocyclic derivative and pharmacological application thereof | FIRST AFFILIATED HOSPITAL SOOCHOW UNIV | 2012-04-04 | — | — | CN | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-7297698-B2 | N-phenyl-(2R,5S) dimethylpiperazine derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-20 | — | — | US | disclosed |
| WO-2007027532-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20050261303-A1 | N-phenyl-(2r,5s) dimethylpiperadine derivative | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1557411-A1 | N-PHENYL-(2R,5S)DIMETHYLPIPERADINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-1997032858-A1 | QUINOXALINE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
| EP-0518530-B1 | Improvements in or relating to excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5196421-A | Treatment of neurological disorders | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0518530-A2 | Improvements in or relating to excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1992-12-16 | — | — | EP | disclosed |
| US-5153196-A | Administering for reduction of neurotransmission in nervous system disorders | ELI LILLY AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261303-A1 | N-phenyl-(2r,5s) dimethylpiperadine derivative | BPHL, QDPR, SRD5A2 | ALDH1A1 172/4885TXNRD1 612/4885TXNRD3 328/4885 |
| US-12286429-B2 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors | F11, F12, F13A1 | ALDH1A1 2307/4885TXNRD1 4032/4885TXNRD3 2497/4885 |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | ALDH1A1 1441/4885TXNRD1 24/4885TXNRD3 76/4885 |
| US-20230064443-A1 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | F11, F12, F13A1 | ALDH1A1 2398/4885TXNRD1 3980/4885TXNRD3 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.